BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Pfizer

Coronavirus variants first found in South Africa and the UK are able to partially "breakthrough" the Pfizer/BioNTech vaccine, according to an Israeli study that studied real-world infection data. The study has not yet been peer-reviewed. The study, released on Saturday, compared the incidences of both variants between vaccinated and unvaccinated patients who had tested positive for the coronavirus. The study, conducted by Tel Aviv University and Israeli healthcare provider Clalit tracked almost 400 people, and counted both partially vaccinated (one dose) and fully vaccinated (two dose) patients.

Pfizer vaccine may be less effective against South African and UK coronavirus variants, according to Israeli study

If investors are expecting BNTX stock to continue generating double digit gains, they should be taking a careful look at its pipeline. The post What Can BioNTech Do for an Encore?

What Can BioNTech Do for an Encore?

Pharmaceutical giant Pfizer announced on Friday that it submitted a request for emergency use authorization to begin administering its COVID-19 vaccine to adolescents between the ages of 12 and 15 in the U.S.

Pfizer requests emergency use authorization to administer COVID-19 vaccine to adolescents

The request comes just days after Pfizer released clinical trial data demonstrating its vaccine was 100% effective and well tolerated by the younger age group.

Pfizer asks FDA to clear its COVID-19 vaccine for use in kids ages 12 to 15

Pfizer's shot could be the first coronavirus vaccine approved for 12- to 15-year-olds.

Pfizer Asks FDA To Approve Its Covid Vaccine For Younger Teenagers

The European Commission is reportedly seeking EU governments' approval to get into talks with Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) to purchase up to 1.8 billion doses of their COVID-19 vaccines to be delivered in 2022 and 2023, Reuters reported. Earlier today, German daily Die Welt reported that the Commission was to sign contracts shortly to buy up to 1.8 billion doses but did not say with which company.

European Union Looks To Buy 1.8B Pfizer-BioNTech COVID-19 Vaccine Doses From 2022: Reuters

Pfizer and BioNTech and requested that US regulatory agencies to make their COVID-19 vaccine available for adolescents aged 12 to 15. In a press release issued on Friday, the companies said they plan to make similar requests worldwide in coming days.

Pfizer and BioNTech have asked US regulators to make their COVID-19 vaccine available to adolescents ages 12 to 15

Shares of Pfizer Inc. gained 1.0% in trading on Friday after the drug maker said it requested that the emergency authorization for its COVID-19 vaccine be amended to include teens between the ages of 12 and 15 years old. The vaccine is currently authorized for people who are at least 16 years old in the U.S. Pfizer said a Phase 3 clinical trial in 12 to 15 years old found that the vaccine is 100% efficacious and had a similar side-effect profile to past study participants between the ages of 16 to 25 years old.

Pfizer requests FDA expand authorization to include 12 to 15 year olds

AbbVie

ACADIA Pharma

Alexion Pharma

AstraZeneca

Biogen

CRISPR Therapeutics

Editas Medicine

Illumina

Kadmon Hlds

Moderna

Regulatory and drug-pricing worries have knocked biotech stocks off their Covid-19 pedestal. After hitting a high point in early February, biotech stocks have collectedly fallen 21%.

Biotech Stocks Hit A Snag — Why Experts Say The Heyday Isn't Over

There are several potential reasons why investors didn't cheer the companies' great news more loudly.

Why Didn't Pfizer and BioNTech Stocks Soar After Their COVID Vaccine Achieved 100% Efficacy in Kids?

The National Institutes of Health (NIH) has begun a mid-stage study to determine the risk of allergic reactions shortly after receiving COVID-19 vaccines made by Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE)/BioNTech SE (NASDAQ: BNTX). Several allergic reaction incidents, including serious episodes known as anaphylaxis, have been reported in the U.S. after vaccinations of Pfizer/BioNTech and Moderna shots.

NIH Starts Study On Allergic Reactions Risk To Pfizer/BioNTech, Moderna COVID-19 Vaccines

Look for sales of the vaccine to be better than expected, too.

Why Pfizer and BioNTech's COVID Vaccine Could Be Even Better Than Expected

Investors may be wondering what comes next for BioNTech SE (NASDAQ:BNTX). That is, what does the German company have behind its Covid-19 vaccine, which it says will generate revenue of $11.5 billion this year.

Investors Wondering What Comes Next for Covid Vaccine Producer BioNTech

Pfizer Inc (NYSE: PFE) is reportedly working on a new COVID-19 vaccine supply deal to Israel after an initial agreement announced in late 2020 has ended. “The company is currently working with the Israeli government to update the agreement, to supply additional vaccines to the country.

Pfizer In Talks With Israel For New COVID-19 Vaccine Supply Deal: Reuters

The country says it hopes to vaccinate teenagers soon, and will likely need doses to provide booster shots.

Pfizer Negotiating Deal to Sell More Covid-19 Vaccine to Israel

Academy Sports and Outdoors

Chewy

Micron Technology

Walgreens

Out of a limited number of earnings reports released in this shortened week, we'll recap here the impact of the week's five best reports.

Best Earnings Reports for Week Ending April 2, 2021

Top-line results from clinical trials also show the jab protects against the so-called South African variant.

Pfizer and BioNTech's Coronavirus Vaccine Remains Effective for at Least 6 Months

In a joint statement on Thursday, Pfizer Inc (NYSE: PFE) and BioNTech (NASDAQ: BNTX) said new data showed their Coronavirus vaccine had an efficacy of over 91% after six months. Initially, in November, the two companies had published data from their late-stage clinical trial that included 44 thousand participants, in which the vaccine was shown […] The post Updated data shows Pfizer/BioNTech COVID-19 vaccine to be 91% effective appeared first on Invezz.

Updated data shows Pfizer/BioNTech COVID-19 vaccine to be 91% effective

Findings based on two doses three weeks apart are first to show shot remains effective for many months

Pfizer vaccine has 91% efficacy for up to six months, trial shows

Snap

BioNTech SE - ADR (NASDAQ: BNTX) shares are trading higher by 2% after the company confirms high efficacy and no serious safety concerns through up to six months following the second dose in the updated topline analysis of the landmark COVID-19 vaccine study. BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19.

What's Going On With BNTX Stock And SNAP Stock Today?

There was welcome news on the COVID-19 vaccine front Thursday, as Pfizer Inc. and German partner BioNTech SE said a follow-up study of their vaccine found it remained safe and highly effective six months after a second dose.

Coronavirus Update: Pfizer and BioNTech say their COVID-19 vaccine is safe and highly effective — including against South Africa variant

BioNTech stock continued a sprint Thursday after the company suggested its Pfizer-partnered Covid vaccine is effective against a mutation first identified in South Africa. The post Pfizer Suggests Covid Vaccine Can Tackle South Africa Variant; BioNTech Pops appeared first on Investor's Business Daily.

Pfizer Suggests Covid Vaccine Can Tackle South Africa Variant; BioNTech Pops

The shares of Pfizer Inc. (NYSE:PFE) are down 0.2% at $36.15 at last check, despite the drug maker posting updated results that showed its Covid-19 vaccine, in partnership with BioNTech (BNTX), is 91% effective for up to six months.

Pfizer Stock Dips Despite Upbeat Covid-19 Vaccine Data

The vaccine has been okayed for emergency use in the U.S. for people aged 16 or older.

Pfizer-BioNtech Vaccine Protects Against South African Variant, ‘Highly Effective' Against Disease For Six Months, Updated Trial Data Shows

Pfizer (PFE) and BioNTech (BNTX) report 100% efficacy for their COVID-19 vaccine in teenagers aged 12 to 15.

News for BioNTech SE Stock (BNTX)